• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Back to Resource Hub Article

Adjunctive Cariprazine for the Treatment of Patients with MDD

Signant Health
Jan 17, 2023
Article

Treating major depressive disorder (MDD) can be challenging since many patients do not respond to initial antidepressant treatment.

Signant’s Clinical Vice President of Mood Disorders Dr. Gary Sachs collaborated with industry colleagues to study the effects of adjunctive cariprazine as treatment for major depressive disorder (MDD).

The results, published in a 2023 issue of the American Journal of Psychiatry, found that cariprazine had a favorable safety and efficacy profile.

Learn more about the study findings by downloading the article below.

READ THE ARTICLE

Similar posts

Looking for more insights? Explore related resources.

BLOG POST

Enhancing Signal Detection in Schizophrenia Clinical Trials

VISIT THE BLOG
CASE STUDY

Signant's Central Rating Services Improved Signal Detection in 5 Major Depressive Disorder Trials

READ THE STUDY
ARTICLE

Audio-digital Recordings for Surveillance in MDD Trials

READ THE ARTICLE

Get notified on new marketing insights

Here mention the benefits of subscribing